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A B S T R A C T
Background
Atopic eczema (AE) is a chronic inflammatory and pruritic skin disease. There is still an unmet need for
topical anti-inflammatory and anti-pruritic substances exhibiting an excellent safety profile. The endocannabi-
noid system is known to regulate various aspects of cutaneous barrier and immune functions, thus targeting it
may be a valid approach for alleviating the symptoms of AE.
Objective
To assess the putative efficacy of Echinacea purpurea-derived alkylamides (Ec. extract) activating
cannabinoid (CB)-2 receptors in exerting anti-inflammatory effects and alleviating symptoms of AE.
Methods
In vitro anti-inflammatory efficiency was investigated by monitoring the effects of Ec. extract on
poly-(I:C)-induced pro-inflammatory cytokine expression (Q-PCR) and release (ELISA) of HaCaT ker-
atinocytes. Irritancy and sensitization potential (assessed by Human Repeat Insult Patch Test; Clinical trial 1);
clinical efficiency in alleviating symptoms of AE (Clinical trial 2) as well as effects on human skin structure
and lipid content (Clinical trial 3 followed by transmission electron microscopy and HPTLC) were investi-
gated in randomized double blind clinical trials.
Results
Ec. extract significantly reduced mRNA expression as well as release of poly-(I:C)-induced pro-inflam-
matory cytokines (IL-6 and IL-8) in keratinocytes. Thus, not surprisingly, the well-tolerated (Clinical trial 1)
Ec. extract-based cream reduced local SCORAD statistically significantly, not only compared to baseline, but
also compared to the comparator (Clinical trial 2). Of great importance, besides the in vitro anti-inflammatory
effects, administration of the Ec. extract-based cream also resulted in significantly higher levels of overall
epidermal lipids, ceramide EOS (ω-esterified fatty acid + sphingosine sphingoid base), and cholesterol at Day
15 compared to baseline as well as significantly greater numbers of intercellular lipid lamellae in the intercel-
lular space (Clinical trial 3).
Conclusion
The investigated Ec. extract shows great potential in alleviating cutaneous symptoms of AE, and by ex-
erting remarkable anti-inflammatory actions and restoring the epidermal lipid barrier, it will be very likely a
well-tolerated, powerful novel ingredient for the adjuvant therapy of AE.
© 2017 Published by Elsevier Ltd.
1. Introduction
Atopic eczema (AE), also known as atopic dermatitis, affects be-
tween 2 and 10% of adults and 15–30% of children, and is considered
to be the most common inflammatory skin condition in childhood [1].
The major clinical symptoms of AE are erythema and pruritus lead
⁎ Corresponding author at: University of Debrecen, Egyetem tér 1., Debrecen, H-4032,
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ing to the well-known itch/scratch cycle [2]. The underlying etiol-
ogy of AE is multifactorial, including a genetic predisposition, defi-
ciencies in the skin of specific polyunsaturated fatty acids (such as
linoleic acid), skin barrier defects, and immune dysfunction, where the
skin barrier defects are considered central [3,4]. Thus, it is not sur-
prising that ceramide levels in the stratum corneum are decreased in
these patients. In a study conducted by Imokawa et al. in the early
1990s, there was a marked reduction in ceramide levels in both le-
sional and non-lesional skin in AE patients, compared with healthy
subjects [5]. Findings from a more recent study suggested that metab
http://dx.doi.org/10.1016/j.jdermsci.2017.05.015
0923-1811/© 2017 Published by Elsevier Ltd.
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olism of sphingomyelin, a precursor to barrier ceramides, is altered in
AE, leading to a decrease in ceramide levels. The resulting ceramide
deficiency may contribute to a disturbed epidermal barrier with in-
creased transepidermal water loss (TEWL) thus leading to dry skin,
another clinical symptom associated with AE [6,7]. Hence, increasing
ceramide levels within the epidermal barrier may improve AE symp-
toms, such as erythema or pruritus.
Currently, emollient treatment is the basic therapy to improve skin
barrier function in addition to the use of topical corticosteroids or im-
mune modulators in AE [8,9]. Moreover, plant-extract containing for-
mulations may add to the basic therapy exhibiting additional effects
and have shown promise in treating mild AE [10]. However, there is
still an unmet need to identify novel therapeutic targets exhibiting “fa-
vorable” side-effect profiles.
The endocannabinoid system (ECS) is a multifaceted signaling
system regulating a wide variety of physiological functions in the cen-
tral nervous system as well as in the periphery, including regulation
and control of the inflammatory/allergic processes [11]. Since there is
a functioning endocannabinoid system (ECS) existing in the skin, tar-
geting it may be a valid approach for alleviating AE symptoms [12]. It
seems that the main physiological function of the cutaneous ECS is to
constitutively control the proper and well-balanced proliferation, dif-
ferentiation and survival, as well as immune competence and/or toler-
ance of skin cells [12].
Indeed, recent data showed that loss of appropriate cannabinoid
signaling exacerbated allergic skin inflammation [13], whereas in-
crease of the endocannabinoid tone by inhibiting fatty acid amide
hydrolase (FAAH; one of the major endocannabinoid degrading en-
zymes) prevented Toll-like receptor activation induced inflammatory
response of human immortalized keratinocytes via indirect activa-
tion of CB1 and CB2 cannabinoid receptors, and substantially alle-
viated skin symptoms of NC/Tnd mice [14]. Collectively, these re-
sults strongly argue for that the homeostatic endocannabinoid sig-
naling may be a crucial gate-keeper in controlling cutaneous im-
mune processes. Moreover, several non-psychotropic phytocannabi-
noids (namely (−)-cannabidiol, (–)-cannabichromene, (–)-cannabidi-
varin, (–)-cannabigerol, (–)-cannabigerovarin and (–)-Δ9-tetrahydro-
cannabivarin) were recently shown to exert promising anti-inflamma-
tory effects in human sebocytes, further arguing for that plant-derived
agents influencing certain branches of the complex cannabinoid sig-
naling may have potential in the management of cutaneous inflamma-
tions [15,16].
It is well-known that Echinacea purpurea and E. angustifolia
preparations are widely used to treat upper respiratory infections,
and it is thought that many of their benefits are due to their im-
munomodulatory properties, including effects on cannabinoid recep-
tors [17,18]. One study showed that Echinacea spp.-derived alky-
lamides (i.e. dodeca-2E,4E,8Z,10Z-tetranoic acid isobutylamide [A1]
and dodeca-2E,4E-dienoic acid isobutylamide [A2]) bind to CB2 re-
ceptor even more strongly than endogenous cannabinoids [19]. In an-
other study, alkylamides from Echinacea extracts were shown to mod-
ulate expression of tumor necrosis factor-α (TNF-α) mRNA in hu-
man macrophages and monocytes via CB2 receptor, and inhibition
of lipopolysaccharide (LPS)-stimulated TNF-α expression by alky-
lamides was also demonstrated [20]. Alkylamides derived from Echi-
nacea spp. have also been shown to partially inhibit the activity of
FAAH [21], indicating that, besides direct CB2 binding, they can also
positively modulate receptor activity by increasing the endocannabi-
noid tone. Based on these data, E. purpurea-derived extracts hold out
the promise to exert beneficial (i.e. anti-inflammatory and anti-pru-
ritic) effects in AE.
To prove the benefit of a water-in-oil (W/O) emulsion contain-
ing an E. purpurea extract for daily skin care of atopic individuals,
an in vitro study was first conducted which assessed putative anti-in-
flammatory effects of the E. purpurea extract in human keratinocytes.
Thereafter, cutaneous tolerability, clinical efficacy and effects on stra-
tum corneum structure and lipid levels of an E. purpurea extract-con-
taining W/O-emulsion were investigated in subjects suffering from
AE.
2. Materials and methods
2.1. Echinacea purpurea extract (Ec. extract)
Echinacea purpurea is cultured according to Good Agricultural
and Collection Practice in the Netherlands, Poland and Ukraine. Fol-
lowing harvest in autumn dried roots are subjected to a quality check
and are stored not exceeding March of next year before the roots are
extracted. The extract is prepared by supercritical CO2-extraction of
Echinacea purpurea roots and alkamide content is analyzed analog to
Sun et al. [22]. The method separates the lipophilic components from
the remaining plant materials and leaves no solvent residues.
The extract is formulated in a cream of the water-in-oil emulsion
type and consists of the following ingredients: Aqua, Decyl Oleate,
Isopropyl Myristate, Carthamus Tinctorius Seed Oil, Hexyldecanol,
Hexyldecyl Laurate, Glycerin, Polyglyceryl-3 Polyricinoleate, Sorbi-
tan Isostearate, Cera Alba, Citrus Aurantium Dulcis Peel Extract, Zinc
Stearate, Benzyl Alcohol, Echinacea Purpurea Root Extract, Mag-
nesium Sulfate, Lecithin, Tocopherol, Ascorbyl Palmitate, Glyceryl
Oleate, Glyceryl Stearate, Citric Acid.
2.2. In vitro study
2.2.1. Materials
The Toll-like receptor 3 activator polyinosinic-polycytidylic acid
(poly-(I:C)) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Poly-(I:C) was dissolved in filtered distilled water, whereas the
solvent for the E. purpurea extract (Ec. extract; provided by Dr. Au-
gust Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany) was
dimethyl sulfoxide (DMSO; VWR International Ltd., Debrecen, Hun-
gary).
2.2.2. Cell culturing
Human immortalized HaCaT keratinocytes were cultured in Dul-
becco’s Modified Eagle Medium (DMEM; Sigma-Aldrich) supple-
mented with 10% fetal bovine serum (Life Technologies Hungary
Ltd., Budapest, Hungary), and antibiotics (MycoZap™ Plus-CL in
1:500; Lonza, Budapest, Hungary) at 37 °C in a 5% CO2-containing
humidified atmosphere. The medium was changed every other day,
and cells were sub-cultured at 70–80% confluence.
2.2.3. RNA isolation, reverse transcription, quantitative “real-time”
PCR (Q-PCR)
RNA isolation, DNase treatment, reverse transcription and Q-PCR
were performed as described previously [14,15,23]. PCR amplifica-
tion was performed by using TaqMan® primers and probes (assay
ID-s: Hs00985639_m1 for IL-6 and Hs00174103_m1 for IL-8) and the
TaqMan® universal PCR master mix protocol (Applied Biosystems).
As internal controls, transcripts of 18S RNA were measured (assay
ID: Hs99999901_s1). The expression of transcripts was normalized to
those of the housekeeping gene, and results were then normalized to
the mRNA expression of the vehicle control (ΔΔCT method).
UN
CO
RR
EC
TE
D
PR
OO
F
Journal of Dermatological Science xxx (2017) xxx-xxx 3
2.2.4. Determination of cytokine release (ELISA)
Cells were treated as indicated for 3 and 24 h. Supernatants were
then collected, and the released amount of IL-6, and IL-8 were deter-
mined using OptEIA kits (BD Pharmingen, Franklin Lakes, NJ, USA)
according to the manufacturer’s protocol.
2.2.5. Statistical analysis
Data were analyzed and graphs were plotted by using Origin Pro
Plus 6.0 software (Microcal, Northampton, MA, USA), using Stu-
dent’s two-tailed two samples t-test (paired comparisons).
2.3. Clinical study 1: irritancy and sensitization potential
2.3.1. Study design
This randomized, double-blind, single-center, placebo-controlled
clinical study was conducted in healthy subjects in Hamburg, Ger-
many in order to determine cutaneous tolerability of the Ec. extract
containing W/O emulsion (WO 3260) by assessing local irritancy and
sensitization potential compared to the very well-tolerated and suc-
cessfully marketed Linola® body lotion (Dr. August Wolff GmbH &
Co. KG Arzneimittel) in a human repeat insult patch (HRIP) test per-
formed as described previously [24].
2.3.2. Patient selection
Of the 105 volunteers recruited, 104 were eligible for data analy-
sis. Inclusion criteria were: aged between 18 and 75 years, skin pho-
totype I–IV, and in general good health. Exclusion criteria included:
acute cutaneous diseases at the skin test sites, known hypersensitivity
to Fixomull® Stretch plasters or to the test products, and application of
topical medication in the test area within the month before study start.
Volunteers were Caucasian, aged between 19.9 and 74.2 years
(mean of 47.9 years ±13.2) and comprised 89 and 15 females and
males, respectively.
2.3.3. Treatment schedule
Induction/irritancy potential phase: test products (i.e. Linola® body
lotion and the Ec extract-containing “WO 3260”) or placebo were
applied 6 times (150 μl per application) to different test sites on the
lower back of each volunteer over a 14-day period (48 h, 48 h, 72 h,
48 h, 48 h, 72 h). Challenge/sensitization potential phase (1 week after
the induction phase): a single 150 μl application of a test product or
placebo was assessed over 48 h.
In both phases, applications were administered with the test patch
device FinnChamber® Large (18 mm) and a Fixomull® Stretch plaster
was subsequently placed over the test site.
As a result of dropouts and treatment discontinuations within the
first 8 days of the study as a result of an erythema score of 1 or higher,
80 of the volunteers were challenged with Linola® body lotion and 85
of the volunteers were challenged with WO 3260.
2.3.4. Safety assessments
Irritancy and sensitization were assessed using a 0–6 point rank-
ing system for erythema. Grading was as follows: 0 = no reaction,
0.5 = slight, patchy erythema, 1 = slight uniform erythema, 2 = mod-
erate, uniform erythema, 3 = strong erythema, 4 = strong erythema,
spreading outside of patch, 5 = strong erythema, spreading outside of
patch with swelling or vesiculation, 6 = severe reaction with erosion.
Any other sign of cutaneous irritancy was also to be recorded. Visual
assessments were performed on days 3, 5, 8, 10, 12 and 15 in the in
duction/irritancy phase and 10 to 30 min and 48 h after patch removal
in the challenge phase. The irritancy potential for each volunteer was
assessed by the Cumulative Irritation Score (calculated as the sum of
the daily scores) during the irritancy phase.
2.3.5. Statistical analysis
For missing data the last observation was carried forward. The
products were compared to each other using Friedman's ANOVA and
post-hoc comparisons (Wilcoxon-Wilcox-Test).
2.4. Clinical study 2: clinical efficacy in patients with AE
2.4.1. Study design
Clinical efficiency was tested in a prospective, randomized, dou-
ble-blind, clinical study conducted at a test center in Hamburg, Ger-
many over a period of 3 months. It is well-known that comparison
with the placebo could result in the preference of the less smelly prod-
uct by the subjects in a clinical trial. Thus, since due to the presence of
the extract, WO 3260 (Linola® Plus Cream, Dr. August Wolff GmbH
& Co. KG Arzneimittel, Germany) has a characteristic odor which
cannot be masked or mimicked efficiently, it was impossible to assess
its efficiency in a placebo-controlled study. Since we wanted to make
sure that the smell would not be a discriminator, we selected a clin-
ically efficient [25] comparator product (Imlan® Creme Pur, Birken
AG, Germany) also possessing a characteristic odor. Thus, the aim
of Clinical study 2 was to compare the effects of WO 3260 with Im-
lan® Creme Pur in patients suffering from AE. The primary endpoint
was the change from baseline in local SCORAD score (sum of scores
for erythema, edema/papules, weeping/crusts, excoriation, lichenifi-
cation, pruritus and dryness) at Day 29, Day 57 and Day 85 in the
per-protocol (PP) population.
2.4.2. Patient selection
Overall, 60 male and female patients were enrolled and comprised
the safety and intention-to-treat (ITT) populations. Of these patients,
11 were excluded (4 due to the test product and 7 for other reasons)
and consequently the PP population comprised 49 patients. Other in-
clusion criteria were: age at least 10 years, AE with at least two slight
eczematous and contralaterally-located subacute or chronic lesions in
the test area without any sign of infection as rated by the dermatolo-
gist or an experienced physician (local SCORAD at least 4; erythema
and pruritus scores at least 1). Exclusion criteria included: active skin
disease other than AE at test area, serious health condition potentially
affecting the test reaction/assessment, topical medication at the treat-
ment area on the day before study start and/or during the study period,
systemic treatment with antiinflammatories, analgesics, immunosup-
pressive drugs, antihistamines and/or antibacterials on the day before
and/or during the study period. Demographic data for the safety/ITT
and PP populations are summarized in Table 1. Flow diagram for pa-
tient inclusion is summarized in Fig. 1.
2.4.3. Randomization and treatment schedule
Validated software (Randomization in Treatment Arms [RITA];
Evidat®, Sereetz, Germany) was used to assign the two test products
to their respective test areas minimizing inter-individual differences in
local SCORAD values. A dermatologist or an experienced physician
identified 2 comparable and contralateral skin areas (crooks of arms,
knee hollow, trunk, wrist or shin) with mild AE lesions. WO 3260
or reference product was applied 2 or 3 times daily. Subjects were
instructed to apply the test product within ‘area 1′ and the reference
product within ‘area 2′ on the contralateral side of their body.
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Table 1
Demographic features of the study population and the per protocol population (Clinical
trial 2).
Population
SP (Enrolled,
N = 60) PP (Valid, N = 49)
Age (mean ± SD [range]) 30.2 ± 15.9 (10–85) 32.5 ± 16.4
(10–85)
Gender (N [%])
female 38 (63.3) 30 (61.2)
male 22 (36.7) 19 (38.8)
Received concomitant diagnosis (N
[%])
60 (100) 49 (100)
On concomitant therapies (N [%]) 32 (53.3) 26 (53.1)
PP = per protocol; SD = standard deviation; SP = safety population.
2.4.4. Clinical assessment
Efficacy was objectively assessed with local SCORAD (sum of 7
SCORAD categories). Local SCORAD is considered to be one of the
best tools for clinical assessment of localized AE [26].
Local SCORAD parameters: Erythema, edema and papules, weep-
ing and crusts, excoriation, lichenification, pruritus on lesions and dry-
ness on the non-lesional areas.
Scale: 0 = None; 1 = Slight; 2 = Moderate; 3 = Strong. The local
SCORAD was calculated as sum of grading of the seven parameters
mentioned above; thus, the maximum value of the local SCORAD
could be “21”.
Besides local SCORAD, subjective efficacy was also assessed by
asking for feeling dryness, burning, tension, tickling or other unpleas-
ant sensations. Scale: 0 = None; 1 = Slight; 2 = Moderate; 3 = Strong.
The subjects also filled in a product acceptance questionnaire with dif-
ferent scores concerning test material traits. Clinical assessments were
performed on Days 29, 57, and 85.
2.4.5. Safety assessments
Adverse reactions in the treatment areas were scored for the rele-
vant parameter at scheduled visits. All adverse reactions were docu-
mented in study records.
2.4.6. Statistical analysis
Computation of the statistical data was performed with a com-
mercially available statistics program (SAS for Windows; SAS Insti-
tute GmbH, Heidelberg, Germany). N, means, standard deviations and
95% confidence limits of all subjects in the population (PP) were cal-
culated for metric scaled data at all assessment times by test product
as well as for calculated parameters. A significance level of 0.05 (al-
pha) was chosen for statistical analysis. Due to the explorative nature
of this study, no adjustments for multiplicity were made. To assess
whether treatments differed in local SCORAD a repeated measure-
ments ANOVA test on the changes from baseline with the factors of
treatment and time and the according interaction was performed. Ad
Fig. 1. Flow diagram for patient inclusion (Clinical trial 2). AR: adverse reaction; ITT: intention-to-treat population; PP: per protocol population; SP: study population.
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ditional paired t-tests were conducted to compare changes from base-
line in local SCORAD at Days 29, 57, and 85 for each treatment and
to compare these changes between treatments.
2.5. Clinical study 3: skin barrier function
2.5.1. Study design
This randomized single-center study conducted in Hamburg, Ger-
many assessed the effects of WO 3260 on skin barrier parameters in
subjects with AE.
2.5.2. Patient selection
A total of 25 male and female subjects were recruited. Other eligi-
bility criteria included: age between 18 and 70 years, skin phototype
I–III, AE with local SCORAD of between 1 and 15.
Overall, 22 were female (88%) and 3 were male (12%). The mean
age was 45.4 (±13.9) years. Fifteen subjects were included in the
transmission electron microscopy (TEM) and lipid analyses.
2.5.3. Treatment schedule
WO 3260 (approximately 2 mg/cm2) was applied twice a day to a
designated test area on the forearm of subjects over a 14-day period.
2.5.4. Skin barrier assessments
Skin barrier assessments were carried out on Day 15. TEM was
used to assess change in ultrastructure and amount of lipid lamellae
in stratum corneum (SC). Components of the intercellular lipid lamel-
lae (ceramide EOS, ceramide NP, ceramide NH, cholesterol, free fatty
acids) were assessed by a lipid analysis (high performance thin layer
chromatography HPTLC).
Both analyses utilized Lipbarvis®, a non-invasive sampling tech-
nique to harvest stratum corneum samples [27]. Therefore, a drop of
the glue was applied to the carrier, which was then placed onto the
skin surface. After polymerization, the carrier with the adhering cor-
neocytes was gently removed from the skin surface. This procedure
was repeated a second time at the same location. This sample was then
used for TEM and for lipid analysis.
A part of the sample was prepared for subsequent TEM analysis
according to Dähnhardt-Pfeiffer et al. [28]. The TEM investigation
with a transmission electron microscope CM10 (FEI, Eindhoven, The
Netherlands) shows the intercellular lipid lamellae in the intercellu-
lar space in the SC samples. In the subsequent morphometric analy-
sis the length of the intercellular lipid lamellae (ICLL) in the intercel-
lular space (ICS) are set into a relationship to the surface area of the
intercellular space and calculated with respect to a reference value of
1000 nm2 (nICLL). This quotient allows a comparison of lipid lamel-
lae between treated and untreated areas of the skin.
2.5.5. Lipid analysis (HPTLC)
At the beginning of the lipid extraction, a photo was taken of the
carrier with the covered corneocytes. Using the ImageJ 1.49 v free-
ware (NIH, Bethesda, MD, USA; http://www.nih.gov/), the corneo-
cyte layer was measured and identified on the sample surface. The
number of cell layers on the carrier was assessed from the TEM data
so that the extracted amount of lipids was referenced to a well-de-
fined circular carrier surface (13 mm diameter) and corneocyte lay-
ers. The extraction of lipids from the corneocytes adhered on the car-
rier (here also referred to as slide) as well as their separation us-
ing HPTLC were carried out according to Imokawa et al. (1991)
[5]. For the chromatographic analysis, Nano-Sil 20 plates (10*10 cm,
Macherrey & Nagel, Düren, Germany) were used. The standard used
contained the lipids cholesterol, ceramides EOS, NP and NH and free
fatty acids.
The HPTLC plates were finally densitometrically measured and
quantitatively analyzed.
2.5.6. Statistical analyses
All Lipbarvis® measurements were presented as mean and standard
deviation, minimum and maximum, as well as quartiles. They were
tested for normal distribution using the Shapiro Wilk test. In case of
significant deviations from normal distribution, non-parametric meth-
ods were used for further statistical analysis otherwise parametric pro-
cedures were used.
Accordingly, measurements in Day 1 and Day 15 as well as the
differences and percentage changes were compared to each other us-
ing Wilcoxon matched pairs test in case of significant deviations from
normal distribution otherwise matched samples t-test was carried out.
All tests performed were two-sided with a significance level of 5%. As
the study was exploratory in nature, no adjustments for multiple test-
ing were made. Statistical analyses were performed with SPSS Statis-
tics 23 software (SPSS Inc. an IBM Company, Chicago, IL).
2.6. Ethics approval for clinical trials
All clinical studies were performed in accordance with the ethical
principles of the Declaration of Helsinki. Prior to study start, full ap-
proval for the protocols, and protocol amendments (if applicable), was
given by the local ethics committees. Written informed consent was
obtained from all patients and volunteers or their respective parents/
legal guardians before entry into the study.
3. Results
3.1. In vitro study
First, we investigated the putative anti-inflammatory effects of
the Ec. extract in vitro. To mimic inflammatory conditions, human,
immortalized HaCaT keratinocytes were treated with poly-(I:C), a
well-known pro-inflammatory agent [13] (20 μg/ml) for 3 h with or
without the Ec. extract or vehicle. We found that the Ec. extract was
able to significantly reduce mRNA expression of IL-6 and IL-8, two
key pro-inflammatory cytokines known to be involved in a wide vari-
ety of cutaneous inflammatory processes [29,30] (Fig. 2A). Moreover,
we could also demonstrate that not only mRNA levels, but also the
biologically even more relevant release of these mediators was signif-
icantly suppressed by the co-administration (Fig. 2B–C), suggesting
that the investigated Ec. extract may possess substantial anti-inflam-
matory activity in vivo as well, especially, since the effects were also
evident following longer-term (i.e. 24-h) experiments (Fig. 2D).
Encouraged by the promising in vitro data, next we tested the ef-
fects of the Ec. extract containing formulation in different clinical
studies in order to i) assess the safety of its application in compari-
son with the already successfully marketed Linola® body lotion (Clin-
ical Study 1); ii) investigate its clinical efficiency in AE in compari-
son with a commercially available, potent comparator product (Imlan®
Creme Pur; Clinical Study 2); and iii) explore how Ec. extract influ-
ence the structure of the epidermal lipid barrier (Clinical Study 3).
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Fig. 2. Echinacea extract efficiently suppresses poly-(I:C)-induced pro-inflammatory cytokine expression and release from HaCaT keratinocytes. (A) Q-PCR analyses of HaCaT
keratinocytes following the indicated 3-h simultaneous treatments. Data are presented by using the ΔΔCT method regarding 18S RNA-normalized mRNA expressions of the vehicle
control as 1 (solid line). Data are expressed as mean ± SD of 2–3 determinations. One additional experiment yielded similar results. (B–D) Determination of the released cytokine
concentration following 3- (B–C) or 24-h (D) simultaneous treatments. Data are presented as mean ± SD of 2–3 determinations. One additional experiment yielded similar results. *,
**, and *** mark significant (P < 0.05, 0.01, and 0.001, respectively) differences as indicated.
3.2. Clinical study 1: irritancy and sensitization potential
3.2.1. Irritancy potential analysis
Evaluation of the HRIP test revealed that both Linola® body lotion
and Ec. extract WO 3260 showed a low to moderate irritancy poten-
tial. Their respective Mean Cumulative Irritation Scores were 1.53 and
1.78, and there were no significant differences between test products.
Moreover, there was no difference between the test products in other
signs of irritation (i.e. pruritus and papules) either.
3.2.2. Sensitization potential analysis
Following a 48-h continuous occlusive application, none of the
products induced erythema grade of 1 or higher on Days 24 and 26
indicating lack of clinically relevant sensitization. Consequently, the
products were considered to have a low sensitization potential. There-
fore we continued our experiments by evaluating clinical efficiency of
WO 3260 compared to a potent, commercially available comparator
product Imlan® Creme Pur.
3.3. Clinical study 2: clinical efficacy in patients with AE
3.3.1. Per-protocol population
Compared with baseline local SCORAD, both WO 3260 and the
comparator resulted in a significant improvement at Day 29 (p < 0.001
or p < 0.001, respectively) and Day 57 (p < 0.001 and p = 0.008, re-
spectively). However, at Day 85, only WO 3260 showed a significant
improvement in local SCORAD versus baseline (p = 0.013). More-
over, this improvement was significantly different as compared to the
reference product (p = 0.047). Results for local SCORAD are shown
in Table 2 and Fig. 3. In addition, the mean local SCORAD area un-
der the curve (AUC) was significantly lower for WO 3260 compared
to the reference product (654.0 vs. 708.5; p = 0.021). Local SCORAD
AUC outcomes are presented in Table 3.
Application of both products resulted in significant improvements
in the pruritus subscore at Day 29, Day 57 and Day 85, compared
with baseline (p < 0.001 for both products at all time points). How-
ever, WO 3260 was associated with a significantly greater improve-
ment from baseline in the pruritus subscore already at Day 57, com
Table 2
Local SCORAD outcomes in the per-protocol population (Clinical trial 2).
Parameter Time p-values of paired t-test
Mean values Mean changes from baseline Changes from baseline Changes from baseline, A vs. B
A B A B A B
SCORAD Day 1 9.6 (N = 48) 9.8 (N = 47)
Day 29 7.2 (N = 46) 7.5 (N = 46) −2.4 (N = 46) −2.3 (N = 46) <0.001* <0.001* 0.489
n.s.
Day 57 7.1 (N = 48) 8.2 (N = 47) −2.5 (N = 48) −1.6 (N = 47) <0.001* 0.008* 0.100
n.s.
Day 85 7.9 (N = 47) 9.3 (N = 47) −1.6 (N = 47) −0.5 (N = 47) 0.013* 0.511
n.s.
0.047*
A: Ec. extract containing cream (WO 3260); B: comparator product (Imlan® Creme Pur).
* Significant difference vs. baseline, p ≤ 0.05. n.s = not significant; SCORAD = SCORing Atopic Dermatitis.
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Fig. 3. Mean change (95% CI) from baseline in local SCORAD in the PP population (N = 46-48; Clinical trial 2). Mean change (95% CI) ±SEM from baseline in local SCORAD.
* Marks significant differences; p < 0.05 in a matched pairs t-test in the comparison of measurement times on raw data; # Marks significant differences; p < 0.05 in a matched pairs
t-test in the comparison of products with respect to changes from baseline.
Table 3
Mean AUC for SCORAD for PP and Results for the Comparison of Products by
Wilcoxon Signed-Ranks Test (N = 44) (Clinical trial 2).
Parameter Mean Median A≠B A < B A > B
A B A B
AUC for SCORAD 654.0 708.5 637.0 721.0 43 28 15
Comparison of Products
by Wilcoxon Signed-
Ranks Test p-values
0.021*
A: Ec. extract containing cream (WO 3260); B: comparator product (Imlan® Creme
Pur).
* Significant difference, p ≤ 0.05; SCORAD = SCORing Atopic Dermatitis.
pared with the reference product (−1.1 vs. −0.7; p = 0.036). In line
with these data, the pruritus subscore AUC was also significantly
lower for WO 3260 compared with the reference product (111.1 vs.
126.0; p = 0.020).
Furthermore, the use WO 3260 was associated with a signifi-
cantly greater improvement from baseline in the erythema subscore at
Days 57 and 85, compared with the reference product (p = 0.022 and
p = 0.028, respectively). Whereas both product showed significant dif-
ferences from baseline in the subscores, there were no significant dif-
ferences between the two products at any of the time points for any of
the other SCORAD subscores.
With respect to subjective dermatological assessments, WO 3260
exhibited a significantly greater improvement from baseline in the
feeling of dryness at Day 85, compared with the reference product
(p = 0.028), and also a significantly greater improvement in ‘tickling
feeling’ at Days 57 and 85 (p = 0.021 and 0.023, respectively).
With respect to acceptance of the Ec. extract containing W/
O-emulsion WO 3260, spreadability was found to be good or very
good for the majority of subjects at Day 29 (89.8% or 67.4%, respec-
tively), Day 57 (81.6% or 69.4%, respectively) and Day 85 (81.6% or
71.4%, respectively) as was the skin feeling after application of the W/
O-emulsion (Day 29: 71.5% or 69.4%; Day 57: 71.4% or 61.2%; Day
85: 67.4% and 53.0%). The majority of subjects considered the greas-
ing effect to be very good or good at all time points and they found
product absorption to be fast or moderate for test and reference. Thus,
having tested and proven the clinical efficiency, we finally intended to
assess if our formulation impacts on the cutaneous lipid barrier.
3.4. Clinical study 3: skin barrier function
3.4.1. TEM assessment
In the morphometric analysis of the TEM images, WO 3260 re-
sulted in a significant increase from day 1 in the number of intercellu-
lar lipid lamellae (ICLL) at Day 15 (74.9 nm/1000 nm2 to 136.8 nm/
1000 nm2; +61.9 nm/1000 nm2, p = 0.001; Fig. 4). Detailed explana-
tion and schematic overview of the measurement can be found on Sup-
plementary Fig. S1.
3.4.2. Lipid analysis assessment
Importantly, as revealed by careful lipid analysis, administration
of WO 3260 led to significant increases from Day 1 in overall lipids
at Day 15 (+9.3 ng/slide; p < 0.001) as well as cholesterol levels
(+2.7 ng/slide; p = 0.005). Moreover, WO 3260 resulted in a signif-
icantly (p = 0.002) higher ceramide EOS (ω-esterified fatty
acid + sphingosine sphingoid base) content in skin at Day 15, com-
pared with baseline (Fig. 5). This was not observed for a linoleic acid
containing water-in-oil emulsion which served as control (compari-
son at day 15; p = 0.047, Wilcoxon matched paired t-test). Non-sig-
nificant increases from baseline in free fatty acids, ceramide NP (non
α-hydroxylated fatty acid + phytosphingosine sphingoid base), and ce-
ramide NH (non α-hydroxylated fatty acid + 6-hydroxy-sphingosine
sphingoid base) were also observed for WO 3260 at Day 15.
4. Discussion
AE is one of the most common human skin diseases, exhibiting
an ever increasing prevalence, especially in the industrial countries
[29–31] Although it is usually not a directly life-threatening prob-
lem, by impairing quality of life of millions world-wide, it results in a
significant psychological and financial burden to the society [29–31]
Hence, there is an emerging demand from both the patients and the
medical community to identify novel, universally efficient, yet safe
medications, ideally exhibiting “favorable” side-effect profiles. To
face this challenge, within the confines of the current highly focused,
multidisciplinary, “bench to bedside” research project involving both
in vitro experiments, as well as in vivo human clinical data, we in-
tended to exploit and evaluate putative beneficial effects of an Ec. ex-
tract, which was already shown to potently activate the anti-inflamma-
tory CB2 receptors [19].
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Fig. 4. Results of Lipbarvis® TEM analysis. (A) TEM images of the intercellular lipid lamellae (arrows) in the intercellular space (labeled between the blue lines) of stratum corneum
samples at Day 1 and after treatment with WO 3260 at Day 15. (B) Mean values of the number of intercellular lipid lamellae (ICLL) in the intercellular space (ICS) and the results
for the comparison on differences to baseline. Data are presented as mean ± SD of N = 10 patients; * marks significant differences; p < 0.05 in a matched pairs t-test.
First, in the in vitro study, anti-inflammatory activity of Ec. extract
in human keratinocytes was demonstrated: we found significant reduc-
tions in poly-(I:C)-induced mRNA expression, as well as in release of
pro-inflammatory cytokines (IL-6 and IL-8) (Fig. 2A–D). These out-
comes are similar to those found in another in vitro study whereby
the Echinacea spp.-derived cannabinoid receptor-binding alkylamides
(“A1” and “A2”) as well as the Echinacea spp.-derived non-CB2 bind-
ing alkylamide undeca-2E-ene,8,10-diynoic acid isobutylamide
(“A3”) significantly inhibited LPS-induced TNF-α, IL-1β and
IL-12p70 expressions (5–500 nM) in a CB2-independent manner at
low nanomolar concentrations; weak modulation of levels of αCD3/
PMA- (phorbol-12-miristate-13-acetate; a well-known activator of
classical and novel protein kinase C isoforms) and αCD28/PMA-stim-
ulated T-cell-derived cytokines was also observed [19].
Having the encouraging data of the in vitro experiments in hand,
an Ec. extract containing W/O emulsion was formulated and inves-
tigated regarding the safety and irritancy potential in a randomized,
double-blind, single-center clinical study by HRIP test (Clinical study
1). Importantly, WO 3260 demonstrated an acceptable and
generally low allergenic potential in a study of volunteers, similar to
the already marketed, and clinically well-tolerated Linola® body lo-
tion and placebo skin creams.
Since WO 3260 may be used two to three times daily, sun expo-
sition of skin treated with the future cosmetic product could happen.
Thus, it is also important to emphasize that none of the known ingre-
dients of the Ec. extract containing emulsion was listed as known pho-
totoxic or photoallergenic agent so far. Indeed, although certain ex-
tracts of E. purpurea (as well as others Echinacea spp.) were shown to
possess UV-mediated activity leading to significant antifungal effects
[32], these compounds were also devoid of phototoxic activity on hu-
man skin, and none of the patients reported sunlight-related side-ef-
fects [33].
Next, we assessed long-term effectiveness of WO 3260 in reduc-
ing local dermatological symptoms associated with AE (erythema,
edema/papules, weeping/crusts, excoriation, lichenification, dryness,
pruritus) in a 3-month prospective, randomized, double-blind, single
center clinical study involving subjects with subacute or chronic AE
(Clinical study 2). The comparator cream, Imlan® Creme Pur, also
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Fig. 5. Determination of lipids in skin using the Lipbarvis® LIPID analysis method. Change from baseline at day 15 in (A) sum of lipids, (B) cholesterol, (C) free fatty acids, (D)
ceramide EOS, (E) ceramide NP, (F) ceramide NH. Data are presented as mean ± SD of N = 9 patients; * marks significant differences; p < 0.05 in a matched pairs t-test.
improved local symptoms, but the effects became weaker after 2
months (Tables 1–3; Fig. 3). Similar short-term improvements with
Imlan® Creme Pur were reported in a study of patients with chronic
dry itchy skin [25]. In contrast, improvements in AE symptoms fol-
lowing application of WO 3260 were sustained for up to 85 days, sug-
gesting that the effects were due to more than mere emollient proper-
ties.
Indeed, assessing effects of WO 3260 on skin barrier, levels of
overall lipids, ceramide EOS, and cholesterol were significantly in-
creased from baseline at Day 15 following a twice-daily application
as were the numbers of intercellular lipid lamellae in the intercellular
spaces (Supplementary Fig. S1; Figs. 4–5). Increased ceramide EOS
levels in the skin barrier have important implications for ameliorat-
ing symptoms of AE as well as for preserving skin barrier integrity.
In another study assessing the effects of an E. purpurea extract-based
cream and gel at 1 month, corneometer hydration indices increased
by 10.6 AU and 11.4 AU, respectively, and wrinkles were found to
decrease by 9.47% and 14.92%, respectively [34]. These results indi
cate that long-lasting beneficial effects of Ec. extract containing WO
3260 cream may be mediated not only by mere emollient effects, but
also by (most probably CB2-mediated) anti-inflammatory actions, as
well as by improvement of the epidermal lipid barrier. However, pos-
itive regulation of cutaneous lipid production by CB2 is not unprece-
dented, since this receptor has already been shown to promote seba-
ceous lipid synthesis of human sebocytes [35]
On the other hand, it is also important to note that other clinical
data also argue for the beneficial effects of topically applied cannabi-
noids in AE. Indeed, an adelmidrol (a novel, palmitoylethanolamide
[PEA] analogue cannabinoid receptor-targeting aliamide) containing
topical emulsion, resulted in complete resolution of lesions in a small
pilot study (N = 20) of patients with mild AE [36]. Furthermore, in
a larger cohort study (N = 2456), a PEA containing cream resulted
in complete resolution of pruritus in 38.3% of patients and signif-
icant improvement in a further 41.0% [37], whereas another study
reported a significant reduction in histamine-induced itch and va-
sodilation following application of topical cannabinoid receptor ag-
onists [38]. Therefore, our study adds to the growing body of ev-
idence demon
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strating that administration of compounds targeting the endocannabi-
noid system may be a valid approach for patients with symptoms as-
sociated with AE and maybe other inflammatory skin diseases as well.
5. Conclusion
Here we presented in vitro as well as clinical data evidencing that
a proprietary E. purpurea extract formulated in a W/O emulsion ex-
erts clinically relevant anti-inflammatory effects, alleviates cutaneous
symptoms and improves epidermal lipid barrier of AE patients. Thus,
this E. purpurea extract-containing W/O-emulsion is a very promising
product for daily medical skin care in subjects with AE.
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